MyoKardia Company Profile (NASDAQ:MYOK)

About MyoKardia (NASDAQ:MYOK)

MyoKardia logoMyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MYOK
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.42 billion
  • Outstanding Shares: 31,489,000
Average Prices:
  • 50 Day Moving Avg: $45.18
  • 200 Day Moving Avg: $45.18
  • 52 Week Range: $10.55 - $49.25
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -23.52
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $43.35 million
  • Price / Sales: 32.80
  • Book Value: $3.95 per share
  • Price / Book: 11.43
  • EBIDTA: ($18,780,000.00)
  • Net Margins: -44.65%
  • Return on Equity: -16.35%
  • Return on Assets: -12.16%
  • Current Ratio: 3.96%
  • Quick Ratio: 3.96%
  • Average Volume: 539,214 shs.
  • Beta: 5.03
  • Short Ratio: 3.93

Frequently Asked Questions for MyoKardia (NASDAQ:MYOK)

What is MyoKardia's stock symbol?

MyoKardia trades on the NASDAQ under the ticker symbol "MYOK."

How were MyoKardia's earnings last quarter?

MyoKardia, Inc. (NASDAQ:MYOK) released its quarterly earnings data on Monday, August, 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.04. The company had revenue of $5.60 million for the quarter, compared to analysts' expectations of $6.73 million. MyoKardia had a negative net margin of 44.65% and a negative return on equity of 16.35%. The firm's revenue for the quarter was up 60.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.37) earnings per share. View MyoKardia's Earnings History.

When will MyoKardia make its next earnings announcement?

MyoKardia is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for MyoKardia.

Where is MyoKardia's stock going? Where will MyoKardia's stock price be in 2017?

5 brokers have issued 12-month price objectives for MyoKardia's stock. Their predictions range from $48.00 to $65.00. On average, they expect MyoKardia's stock price to reach $55.00 in the next twelve months. View Analyst Ratings for MyoKardia.

Are investors shorting MyoKardia?

MyoKardia saw a increase in short interest in the month of August. As of August 15th, there was short interest totalling 1,304,294 shares, an increase of 61.0% from the July 31st total of 810,291 shares. Based on an average daily trading volume, of 1,885,680 shares, the short-interest ratio is presently 0.7 days. Approximately 7.8% of the shares of the stock are short sold.

Who are some of MyoKardia's key competitors?

Who are MyoKardia's key executives?

MyoKardia's management team includes the folowing people:

  • Tassos Anastasios Gianakakos, President, Chief Executive Officer, Director
  • June Lee M.D., Chief Operating Officer
  • Jake Bauer, Senior Vice President - Finance and Corporate Development
  • Joseph Lambing Ph.D., Senior Vice President - Nonclinical and Pharmaceutical Development
  • Robert Scott McDowell Ph.D., Senior Vice President - Drug Discovery
  • Marc Semigran M.D., Chief Medical Officer
  • Mark L. Perry J.D., Interim Non-Executive Chairman of the Board, Lead Independent Director
  • Kevin P. Starr, Director
  • Sunil Agarwal M.D., Independent Director
  • Mary B. Cranston, Independent Director

Who owns MyoKardia stock?

MyoKardia's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (8.62%), Vanguard Group Inc. (2.43%), JPMorgan Chase & Co. (1.52%), State Street Corp (0.74%), Northern Trust Corp (0.65%) and Marshall Wace North America L.P. (0.49%). Company insiders that own MyoKardia stock include Anastasios Gianakakos, Jake Bauer, Jonathan C Fox, Joseph Lambing, Kevin P Starr, Mark L Perry, Rock Ventures Ii LP Third, Sanofi and Wendy L Yarno. View Institutional Ownership Trends for MyoKardia.

Who sold MyoKardia stock? Who is selling MyoKardia stock?

MyoKardia's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, HarbourVest Partners LLC, Trexquant Investment LP, Goldman Sachs Group Inc., Dynamic Technology Lab Private Ltd and Victory Capital Management Inc.. Company insiders that have sold MyoKardia stock in the last year include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, Kevin P Starr and Rock Ventures Ii LP Third. View Insider Buying and Selling for MyoKardia.

Who bought MyoKardia stock? Who is buying MyoKardia stock?

MyoKardia's stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., OxFORD Asset Management LLP, Vanguard Group Inc., TIAA CREF Investment Management LLC, Northern Trust Corp, Essex Investment Management Co. LLC, State Street Corp and Marshall Wace North America L.P.. Company insiders that have bought MyoKardia stock in the last two years include Anastasios Gianakakos, Jonathan C Fox, Mark L Perry, Sanofi and Wendy L Yarno. View Insider Buying and Selling for MyoKardia.

How do I buy MyoKardia stock?

Shares of MyoKardia can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MyoKardia's stock price today?

One share of MyoKardia stock can currently be purchased for approximately $45.15.

MarketBeat Community Rating for MyoKardia (NASDAQ MYOK)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about MyoKardia and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for MyoKardia (NASDAQ:MYOK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $55.00 (21.82% upside)

Analysts' Ratings History for MyoKardia (NASDAQ:MYOK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/20/2017WedbushReiterated RatingOutperform$51.00HighView Rating Details
9/19/2017Credit Suisse GroupReiterated RatingOutperform -> Outperform$45.00 -> $55.00HighView Rating Details
8/21/2017BMO Capital MarketsReiterated RatingOutperform$45.00 -> $65.00HighView Rating Details
8/7/2017Cowen and CompanyBoost Price TargetOutperform$28.00 -> $56.00HighView Rating Details
8/7/2017Wells Fargo & CompanyReiterated RatingOutperform$31.00 -> $48.00HighView Rating Details
(Data available from 9/23/2015 forward)


Earnings History for MyoKardia (NASDAQ:MYOK)
Earnings by Quarter for MyoKardia (NASDAQ:MYOK)
Earnings History by Quarter for MyoKardia (NASDAQ MYOK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.42)N/AView Earnings Details
8/7/2017Q2 2017($0.37)($0.41)$6.73 million$5.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.36)($0.37)$7.00 million$5.60 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.18)$0.44$3.55 million$28.60 millionViewN/AView Earnings Details
11/7/2016Q316($0.07)($0.35)$4.83 million$3.55 millionViewN/AView Earnings Details
8/9/2016Q216($0.33)($0.37)$3.55 million$3.55 millionViewN/AView Earnings Details
5/12/2016Q1($0.53)($0.32)$3.55 million$3.55 millionViewN/AView Earnings Details
3/18/2016Q4($0.68)($0.48)$3.55 million$3.55 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for MyoKardia (NASDAQ:MYOK)
2017 EPS Consensus Estimate: ($1.47)
2018 EPS Consensus Estimate: ($1.74)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.29)($0.29)($0.29)
Q2 20171($0.39)($0.39)($0.39)
Q3 20171($0.39)($0.39)($0.39)
Q4 20171($0.40)($0.40)($0.40)
Q1 20181($0.41)($0.41)($0.41)
Q2 20181($0.43)($0.43)($0.43)
Q3 20181($0.44)($0.44)($0.44)
Q4 20181($0.46)($0.46)($0.46)
(Data provided by Zacks Investment Research)


Dividend History for MyoKardia (NASDAQ:MYOK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for MyoKardia (NASDAQ:MYOK)
Insider Ownership Percentage: 46.10%
Institutional Ownership Percentage: 42.94%
Insider Trades by Quarter for MyoKardia (NASDAQ:MYOK)
Institutional Ownership by Quarter for MyoKardia (NASDAQ:MYOK)
Insider Trades by Quarter for MyoKardia (NASDAQ:MYOK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/11/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell221,250$41.30$9,137,625.00View SEC Filing  
9/8/2017Kevin P StarrDirectorSell201,250$41.01$8,253,262.50View SEC Filing  
9/5/2017Anastasios GianakakosInsiderSell4,300$43.02$184,986.00View SEC Filing  
8/22/2017Joseph LambingInsiderSell5,000$45.00$225,000.00View SEC Filing  
8/15/2017Joseph LambingInsiderSell5,000$40.00$200,000.00View SEC Filing  
8/14/2017SanofiMajor ShareholderBuy350,000$35.50$12,425,000.00View SEC Filing  
8/14/2017Wendy L YarnoDirectorBuy1,408$35.50$49,984.00View SEC Filing  
8/8/2017Joseph LambingInsiderSell15,000$30.00$450,000.00View SEC Filing  
8/7/2017Jake BauerInsiderSell15,000$28.33$424,950.00View SEC Filing  
8/4/2017Anastasios GianakakosCEOSell4,300$16.62$71,466.00View SEC Filing  
7/25/2017Anastasios GianakakosInsiderSell32,988$15.00$494,820.00View SEC Filing  
3/20/2017Anastasios GianakakosCEOSell1,412$15.00$21,180.00View SEC Filing  
3/20/2017Jake BauerInsiderSell667$15.00$10,005.00View SEC Filing  
10/3/2016SanofiMajor ShareholderBuy450,000$15.00$6,750,000.00View SEC Filing  
11/3/2015Anastasios GianakakosCEOBuy1,350$10.00$13,500.00View SEC Filing  
11/3/2015Jonathan C FoxInsiderBuy3,000$10.00$30,000.00View SEC Filing  
11/3/2015Mark L PerryDirectorBuy5,000$10.00$50,000.00View SEC Filing  
11/3/2015SanofiMajor ShareholderBuy900,000$10.00$9,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for MyoKardia (NASDAQ:MYOK)
Latest Headlines for MyoKardia (NASDAQ:MYOK)
DateHeadline logoMyoKardia, Inc. (MYOK) Receives Outperform Rating from Wedbush - September 20 at 11:50 AM logoMyoKardia's (MYOK) Outperform Rating Reaffirmed at Credit Suisse Group - September 19 at 8:58 AM logoMyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly - September 19 at 12:55 AM logoMyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of America’s 21st Annual Scientific Meeting - September 19 at 12:55 AM logoMyoKardia Unveils More Phase 2 Data on Heart Disease Treatment - September 19 at 12:55 AM logoContrasting MyoKardia (MYOK) and Ocata Therapeutics (OCAT) - September 17 at 12:54 PM logoKevin P. Starr Sells 201,250 Shares of MyoKardia, Inc. (MYOK) Stock - September 12 at 7:34 PM logoRock Ventures Ii L.P. Third Sells 221,250 Shares of MyoKardia, Inc. (MYOK) Stock - September 12 at 7:34 PM logoAnastasios Gianakakos Sells 4,300 Shares of MyoKardia, Inc. (MYOK) Stock - September 7 at 8:08 PM logoHead-To-Head Review: Cerulean Pharma (DARE) versus MyoKardia (MYOK) - September 7 at 10:03 AM logoMyoKardia, Inc. (MYOK) Given Consensus Recommendation of "Buy" by Brokerages - September 6 at 6:46 PM logoMyoKardia to Present at Two Upcoming Investor Conferences in September - August 31 at 7:34 AM logoShort Interest in MyoKardia, Inc. (MYOK) Increases By 61.0% - August 28 at 1:48 AM logoInsider Selling: MyoKardia, Inc. (MYOK) Insider Sells 5,000 Shares of Stock - August 24 at 7:34 PM logoMyoKardia, Inc. (MYOK) Rating Reiterated by BMO Capital Markets - August 21 at 10:40 AM logoMyoKardia (MYOK) Looks Good: Stock Adds 6.32% in Session - August 17 at 5:39 AM logoMyoKardia, Inc. (MYOK) Director Wendy L. Yarno Acquires 1,408 Shares - August 16 at 9:34 PM logoMyoKardia, Inc. (MYOK) Insider Sells $200,000.00 in Stock - August 16 at 8:46 PM logoMyoKardia, Inc. (MYOK) Major Shareholder Sanofi Acquires 350,000 Shares - August 16 at 1:40 PM logoWedbush Weighs in on MyoKardia, Inc.'s Q3 2017 Earnings (NASDAQ:MYOK) - August 14 at 2:30 AM logoMyoKardia, Inc. (MYOK) Receives Average Recommendation of "Buy" from Analysts - August 12 at 6:38 PM logoMyoKardia to Present at 2017 Wedbush PacGrow Healthcare Conference - August 11 at 6:45 AM logoMyoKardia, Inc. (NASDAQ:MYOK) Insider Jake Bauer Sells 15,000 Shares - August 9 at 8:44 PM logoMyoKardia, Inc. (NASDAQ:MYOK) Insider Sells $450,000.00 in Stock - August 9 at 8:22 PM logoMyoKardia Inc. (MYOK) Soared To A New High On Phase 2 Study Results - August 9 at 3:35 PM logo[$$] Zinsli's Take: Biotech's Saviors Keep Up VCs' Hopes - August 9 at 3:35 PM logoHere's Why Myokardia Inc. Stock Shot Up Today - August 9 at 2:14 AM logoMyoKardia Shares Almost Double on Latest Clinical Data for Heart Disease Treatment - August 9 at 2:14 AM logoMyoKardia Inc. Is on the Rise Again Today -- Here's Why - August 9 at 2:13 AM logoEdited Transcript of MYOK earnings conference call or presentation 7-Aug-17 12:30pm GMT - August 9 at 2:13 AM logoMyoKardia Announces Pricing of Public Offering of Common Stock - August 9 at 2:13 AM logoMyoKardia, Inc. (NASDAQ:MYOK) Rating Increased to Hold at ValuEngine - August 7 at 11:14 PM logoMyoKardia, Inc. (NASDAQ:MYOK) Given New $56.00 Price Target at Cowen and Company - August 7 at 10:36 PM logoMyoKardia shares surge 32% on positive mid-stage trial results for heart muscle disease - August 7 at 8:16 PM logoMyoKardia Reports Second Quarter 2017 Financial Results and Operational Progress - August 7 at 8:16 PM logoMyoKardia reports 2Q loss - August 7 at 8:16 PM logoMyoKardia, Inc. (NASDAQ:MYOK) Given "Outperform" Rating at Wells Fargo & Company - August 7 at 11:20 AM logoMyoKardia, Inc. (NASDAQ:MYOK) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS - August 7 at 8:50 AM logoMyoKardia, Inc. (NASDAQ:MYOK) Raised to Strong-Buy at BidaskClub - August 5 at 6:44 PM logoRecro Pharma (REPH) & MyoKardia (MYOK) Head to Head Review - August 5 at 12:10 AM logoMyoKardia, Inc. (NASDAQ:MYOK) CEO Anastasios Gianakakos Sells 4,300 Shares - August 4 at 10:32 PM logoMyoKardia to Announce Second Quarter 2017 Financial Results and Host Conference Call on Monday, August 7, 2017 - July 31 at 9:28 PM logoMyoKardia, Inc. (NASDAQ:MYOK) Insider Sells $494,820.00 in Stock - July 27 at 7:43 PM logoETFs with exposure to MyoKardia, Inc. : July 24, 2017 - July 25 at 5:31 AM logoMyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : July 21, 2017 - July 22 at 6:45 AM logoMyoKardia, Inc. (NASDAQ:MYOK) Given Consensus Rating of "Buy" by Brokerages - July 18 at 6:56 PM logoETFs with exposure to MyoKardia, Inc. : July 14, 2017 - July 15 at 6:45 AM logoMyoKardia, Inc. – Value Analysis (NASDAQ:MYOK) : July 12, 2017 - July 13 at 7:06 AM logoMyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : July 11, 2017 - July 12 at 5:47 AM logoMyoKardia, Inc. (NASDAQ:MYOK) Upgraded at TheStreet - July 11 at 11:54 AM



MyoKardia (MYOK) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by Staff